Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report

Fionnuala Crowley; Bailey G. Fitzgerald; Aarti S. Bhardwaj; Irine Siraj; Cardinale Smith

doi:10.1016/j.jtocrr.2021.100260

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report

Fionnuala Crowley, Bailey G. Fitzgerald, Aarti S. Bhardwaj, Irine Siraj, Cardinale Smith

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Osimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis have been previously reported in the literature; however, none have resulted in life-threatening oropharyngeal and respiratory muscle weakness as seen in this case. Care should be taken in administering osimertinib concurrently with other medications metabolized by the CYP3A4 system, and ongoing work to identify patients at risk for severe reactions is necessary. The use of routine creatinine phosphokinase monitoring should be considered as part of oncologic management.

Original language	English
Article number	100260
Journal	JTO Clinical and Research Reports
Volume	3
Issue number	1
DOIs	https://doi.org/10.1016/j.jtocrr.2021.100260
State	Published - Jan 2022

Keywords

Case report
EGFR
Myositis
NSCLC
Osimertinib

Access to Document

10.1016/j.jtocrr.2021.100260

Cite this

@article{64d2da3233ce469ca21a82a1e8db70c1,

title = "Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report",

abstract = "Osimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis have been previously reported in the literature; however, none have resulted in life-threatening oropharyngeal and respiratory muscle weakness as seen in this case. Care should be taken in administering osimertinib concurrently with other medications metabolized by the CYP3A4 system, and ongoing work to identify patients at risk for severe reactions is necessary. The use of routine creatinine phosphokinase monitoring should be considered as part of oncologic management.",

keywords = "Case report, EGFR, Myositis, NSCLC, Osimertinib",

author = "Fionnuala Crowley and Fitzgerald, {Bailey G.} and Bhardwaj, {Aarti S.} and Irine Siraj and Cardinale Smith",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors",

year = "2022",

month = jan,

doi = "10.1016/j.jtocrr.2021.100260",

language = "English",

volume = "3",

journal = "JTO Clinical and Research Reports",

issn = "2666-3643",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib

T2 - Case Report

AU - Crowley, Fionnuala

AU - Fitzgerald, Bailey G.

AU - Bhardwaj, Aarti S.

AU - Siraj, Irine

AU - Smith, Cardinale

PY - 2022/1

Y1 - 2022/1

N2 - Osimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis have been previously reported in the literature; however, none have resulted in life-threatening oropharyngeal and respiratory muscle weakness as seen in this case. Care should be taken in administering osimertinib concurrently with other medications metabolized by the CYP3A4 system, and ongoing work to identify patients at risk for severe reactions is necessary. The use of routine creatinine phosphokinase monitoring should be considered as part of oncologic management.

AB - Osimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis have been previously reported in the literature; however, none have resulted in life-threatening oropharyngeal and respiratory muscle weakness as seen in this case. Care should be taken in administering osimertinib concurrently with other medications metabolized by the CYP3A4 system, and ongoing work to identify patients at risk for severe reactions is necessary. The use of routine creatinine phosphokinase monitoring should be considered as part of oncologic management.

KW - Case report

KW - EGFR

KW - Myositis

KW - NSCLC

KW - Osimertinib

UR - http://www.scopus.com/inward/record.url?scp=85121809108&partnerID=8YFLogxK

U2 - 10.1016/j.jtocrr.2021.100260

DO - 10.1016/j.jtocrr.2021.100260

M3 - Article

AN - SCOPUS:85121809108

SN - 2666-3643

VL - 3

JO - JTO Clinical and Research Reports

JF - JTO Clinical and Research Reports

IS - 1

M1 - 100260

ER -

Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report

Abstract

Keywords

Access to Document

Fingerprint

Cite this